Table 4 Thirty-day rates of major... | American Society of Hematology

Table 4

Thirty-day rates of major outcomes after procedures

Event	Apixaban	Warfarin	OR (95% CI)‡
Event	Events*/procedures (%) [n]†	Events*/procedures (%) [n]†	OR (95% CI)‡
Stroke/systemic embolism	16/4624 (0.35)	26/4530 (0.57)	0.601 (0.322-1.120)
Myocardial infarction	12/4624 (0.26)	18/4530 (0.40)	0.652 (0.312-1.356)
All-cause death	54/4624 (1.17)	49/4530 (1.08)	1.082 (0.733-1.598)
Major bleeding	74/4560 (1.62) [8]	86/4454 (1.93) [11]	0.846 (0.614-1.166)
Major/CRNM bleeding	133/4560 (2.92) [8]	154/4454 (3.46) [12]	0.854 (0.670-1.089)

Event	Apixaban	Warfarin	OR (95% CI)‡
Event	Events*/procedures (%) [n]†	Events*/procedures (%) [n]†	OR (95% CI)‡
Stroke/systemic embolism	16/4624 (0.35)	26/4530 (0.57)	0.601 (0.322-1.120)
Myocardial infarction	12/4624 (0.26)	18/4530 (0.40)	0.652 (0.312-1.356)
All-cause death	54/4624 (1.17)	49/4530 (1.08)	1.082 (0.733-1.598)
Major bleeding	74/4560 (1.62) [8]	86/4454 (1.93) [11]	0.846 (0.614-1.166)
Major/CRNM bleeding	133/4560 (2.92) [8]	154/4454 (3.46) [12]	0.854 (0.670-1.089)

CRNM, clinically relevant nonmajor.

First unique event per procedure.

[n] represents number of bleedings followed by death within 30 days.

OR (95% CI) for apixaban vs warfarin.